Super	O
-	O
enhancers	O
define	O
a	O
proliferative	O
PGC	B-GENE
-	I-GENE
1alpha	E-GENE
-	O
expressing	O
melanoma	O
subgroup	O
sensitive	O
to	O
BET	O
inhibition	O
.	O


Metabolic	O
changes	O
are	O
linked	O
to	O
epigenetic	O
reprogramming	O
and	O
play	O
important	O
roles	O
in	O
several	O
tumor	O
types	O
.	O
PGC	B-GENE
-	I-GENE
1alpha	E-GENE
is	O
a	O
transcriptional	O
coactivator	O
controlling	O
mitochondrial	O
biogenesis	O
and	O
is	O
linked	O
to	O
oxidative	O
phosphorylation	O
.	O


We	O
provide	O
evidence	O
that	O
melanoma	O
models	O
with	O
elevated	O
PGC	B-GENE
-	I-GENE
1alpha	E-GENE
levels	O
are	O
characteristic	O
of	O
the	O
proliferative	O
phenotype	O
and	O
are	O
sensitive	O
to	O
bromodomain	O
and	O
extra	O
-	O
terminal	O
domain	O
(	O
BET	O
)	O
inhibitor	O
treatment	O
.	O


A	O
super	O
-	O
enhancer	O
region	O
highly	O
occupied	O
by	O
the	O
BET	O
family	O
member	O
BRD4	S-GENE
was	O
identified	O
for	O
the	O
PGC	B-GENE
-	I-GENE
1alpha	E-GENE
gene	O
.	O


BET	O
inhibitor	O
treatment	O
prevented	O
this	O
interaction	O
,	O
leading	O
to	O
a	O
dramatic	O
reduction	O
of	O
PGC	B-GENE
-	I-GENE
1alpha	E-GENE
expression	O
.	O


Accordingly	O
,	O
BET	O
inhibition	O
diminished	O
respiration	O
and	O
mitochondrial	O
function	O
in	O
cells	O
.	O


In	O
vivo	O
,	O
melanoma	O
models	O
with	O
high	O
PGC	B-GENE
-	I-GENE
1alpha	E-GENE
expression	O
strongly	O
responded	O
to	O
BET	O
inhibition	O
by	O
reduction	O
of	O
PGC	B-GENE
-	I-GENE
1alpha	E-GENE
and	O
impaired	O
tumor	O
growth	O
.	O


Altogether	O
,	O
our	O
findings	O
identify	O
epigenetic	O
regulatory	O
elements	O
that	O
define	O
a	O
subset	O
of	O
melanomas	O
with	O
high	O
sensitivity	O
to	O
BET	O
inhibition	O
,	O
which	O
opens	O
up	O
the	O
opportunity	O
to	O
define	O
melanoma	O
patients	O
most	O
likely	O
to	O
respond	O
to	O
this	O
treatment	O
,	O
depending	O
on	O
their	O
tumor	O
characteristics	O
.	O
